Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 22.04.2019 2 AJR Am J Roentgenol 1 BMC Urol 1 Cancer 1 Cancer Res 4 Clin Cancer Res 5 Eur Urol 1 Int J Radiat Oncol Biol Phys 1 Invest Radiol 2 J Nucl Med 1 J Urol 2 Lancet Oncol 1 Mod Pathol 1 Oncogene 1 Oncol Rep 1 Oncology (Williston Park) 2 PLoS One 3 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. YADAV MP, Ballal S, Sahoo RK, Dwivedi SN, et al
   Radioligand Therapy With (177)Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
   AJR Am J Roentgenol. 2019 Apr 17:1-11. doi: 10.2214/AJR.18.20845.
   PubMed     Text format     Abstract available
   
   
2. WIBULPOLPRASERT P, Raman SS, Hsu W, Margolis DJA, et al
   Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation.
   AJR Am J Roentgenol. 2019 Apr 17:W1-W10. doi: 10.2214/AJR.18.20113.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

3. VAN DER AA AAMA, Mannaerts CK, Gayet MCW, van der Linden JC, et al
   Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study.
   BMC Urol. 2019;19:23.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

4. PRINTZ C
   Some black men may have more aggressive prostate cancer than scoring indicates.
   Cancer. 2019;125:1398-1399.
   PubMed     Text format    
   
   

   
   Cancer Res

5. JIANG S, Wang X, Song D, Liu X, et al
   Cholesterol induces epithelial-to-mesenchymal transition of prostate cancer cells by suppressing degradation of EGFR through APMAP.
   Cancer Res. 2019 Apr 15. pii: 0008-5472.CAN-18-3295.
   PubMed     Text format     Abstract available
   
   

   
   Clin Cancer Res

6. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
   Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
   Clin Cancer Res. 2019;25:2672.
   PubMed     Text format    
   
   
7. BERNEMANN C, Humberg V, Thielen B, Steinestel J, et al
   Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer.
   Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-4276.
   PubMed     Text format     Abstract available
   
   
8. WEST JB, Dinh MN, Brown JS, Zhang J, et al
   Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: An evolution-based strategy.
   Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-19-0006.
   PubMed     Text format     Abstract available
   
   
9. MAZZU YZ, Armenia J, Chakraborty G, Yoshikawa Y, et al
   A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2).
   Clin Cancer Res. 2019 Apr 17. pii: 1078-0432.CCR-18-4046.
   PubMed     Text format     Abstract available
   
   

   
   Eur Urol

10. SANDLER KA, Cook RR, Ciezki JP, Ross AE, et al
    Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
    Eur Urol. 2019 Apr 13. pii: S0302-2838(19)30208.
    PubMed     Text format     Abstract available
    
    
11. MINERVINI A, Mari A, Campi R, Carini M, et al
    Re: Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30271.
    PubMed     Text format    
    
    
12. KRETSCHMER A, Tilki D
    Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30260.
    PubMed     Text format    
    
    
13. HORN T, Kronke M, Rauscher I, Haller B, et al
    Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30278.
    PubMed     Text format     Abstract available
    
    
14. YAXLEY JW
    Will Favourable Functional Results with Salvage Robot-assisted Laparoscopic Radical Prostatectomy Increase the Uptake of Primary Focal Therapy for Localised Prostate Cancer?
    Eur Urol. 2019 Apr 9. pii: S0302-2838(19)30264.
    PubMed     Text format    
    
    

    
    Int J Radiat Oncol Biol Phys

15. ALAYED Y, Loblaw A, Chu W, Al-Hanaqta M, et al
    Stereotactic Body Radiotherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Dose Escalation Study.
    Int J Radiat Oncol Biol Phys. 2019 Apr 16. pii: S0360-3016(19)30624.
    PubMed     Text format     Abstract available
    
    

    
    Invest Radiol

16. PANDA A, O'Connor G, Lo WC, Jiang Y, et al
    Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.
    Invest Radiol. 2019 Apr 12. doi: 10.1097/RLI.0000000000000569.
    PubMed     Text format     Abstract available
    
    

    
    J Nucl Med

17. JANSEN BHE, Yaqub M, Voortman J, Cysouw MCF, et al
    Simplified Methods for Quantification of (18)F-DCFPyL Uptake in Patients with Prostate Cancer.
    J Nucl Med. 2019 Apr 18. pii: jnumed.119.227520. doi: 10.2967/jnumed.119.227520.
    PubMed     Text format     Abstract available
    
    
18. ROUSSEAU E, Wilson D, Lacroix-Poisson F, Krauze A, et al
    A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.
    J Nucl Med. 2019 Apr 12. pii: jnumed.119.226381. doi: 10.2967/jnumed.119.226381.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

19. RICHIE JP
    Re: Association between Vasectomy and Risk of Testicular Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:667-668.
    PubMed     Text format    
    
    

    
    Lancet Oncol

20. SAAD F
    Importance of early treatment in metastatic prostate cancer: a question of life or death.
    Lancet Oncol. 2019 Apr 12. pii: S1470-2045(19)30155.
    PubMed     Text format    
    
    
21. FIZAZI K, Tran N, Fein L, Matsubara N, et al
    Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2019 Apr 12. pii: S1470-2045(19)30082.
    PubMed     Text format     Abstract available
    
    

    
    Mod Pathol

22. HAMMARSTEN P, Josefsson A, Thysell E, Lundholm M, et al
    Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
    Mod Pathol. 2019 Apr 12. pii: 10.1038/s41379-019-0260.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

23. COLEMAN DJ, Gao L, King CJ, Schwartzman J, et al
    BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer.
    Oncogene. 2019 Apr 17. pii: 10.1038/s41388-019-0815.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

24. ZHANG J, Wang J, Luan T, Zuo Y, et al
    Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics.
    Oncol Rep. 2019 Apr 18. doi: 10.3892/or.2019.7131.
    PubMed     Text format     Abstract available
    
    

    
    Oncology (Williston Park)

25. CONSIDINE B, Petrylak DP
    Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
    Oncology (Williston Park). 2019;33:128-31.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

26. MATZKIN H, Chen J, Agai R, Ziv-Baran T, et al
    Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
    PLoS One. 2019;14:e0215582.
    PubMed     Text format     Abstract available
    
    
27. GUENTHER E, Klein N, Zapf S, Weil S, et al
    Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
    PLoS One. 2019;14:e0215093.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

28. 
    Re: Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. The Prostate. 2019;1-7.
    Prostate. 2019;79:813-814.
    PubMed     Text format    
    
    
29. VIDOTTO T, Saggioro FP, Jamaspishvili T, Chesca DL, et al
    PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Prostate. 2019 Apr 18. doi: 10.1002/pros.23808.
    PubMed     Text format     Abstract available
    
    
30. HONDA M, Kimura T, Kamata Y, Tashiro K, et al
    Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Prostate. 2019 Apr 18. doi: 10.1002/pros.23816.
    PubMed     Text format     Abstract available
    
    

    
    Urology

31. HOFFMANN MA, Wieler HJ, Baues C, Kuntz NJ, et al
    The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
    Urology. 2019 Apr 12. pii: S0090-4295(19)30342.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: